EYPT - EyePoint Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street
Suite B300
Watertown, MA 02472
United States
617-926-5000
http://eyepointpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees84

Key Executives

NameTitlePayExercisedYear Born
Ms. Nancy S. LurkerPres, CEO & Director736.41kN/A1957
Mr. George O. ElstonCFO & Head of Corp. Devel.489.15kN/A1965
Dr. Dario A. PaggiarinoSr. VP & Chief Medical Officer541.39kN/A1957
Mr. Said SaimChief Technology OfficerN/AN/A1958
Mr. Ron I. Honig Esq.Sr. VP, Gen. Counsel & Company Sec.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Corporate Governance

EyePoint Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 6. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.